Kotani, K, Serban, M-C, Penson, P and Lippi, G (2016) Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – some answers and still many questions. Critical Reviews in Clinical Laboratory Sciences, 53 (6). pp. 370-378. ISSN 1549-781X

Preview

Text Revised)CRCLS)Lipoprotein(a) review.pdf - Accepted Version Download (504kB) | Preview

Abstract

The present article is aimed to outline the current state of knowledge regarding the effects of lipoprotein(a) (Lp(a)) on cardiovascular disease (CVD) risk by summarizing the recent results of studies, meta-analyses and systematic reviews. The literature supports the predictive value of Lp(a) on CVD outcomes, although the effect size is modest. Lp(a) would also appear to have an effect on cerebrovascular outcomes, with the effect appearing even smaller than that for CVD outcomes. Consideration of apolipoprotein apolipoprotein(a) (apo (a)) isoforms and LPA genetics in relation to the simple assessment of Lp(a) concentration may enhance improving clinical practice in vascular medicine. We also describe recent advances in Lp(a) research (including therapies) and highlight areas where further research is needed such as the measurement of Lp(a) and its involvement in additional pathophysiological processes.

Item Type:	Article
Additional Information:	This is an Accepted Manuscript of an article published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences on 1/11/16, available online: http://dx.doi.org/10.1080/10408363.2016.1188055
Uncontrolled Keywords:	11 Medical And Health Sciences
Subjects:	R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy & Biomolecular Sciences
Publisher:	Taylor & Francis
Date Deposited:	09 May 2016 10:05
Last Modified:	20 Apr 2022 10:01
DOI or ID number:	10.1080/10408363.2016.1188055
URI:	https://researchonline.ljmu.ac.uk/id/eprint/3584

View Item